The 7 most recent market catalysts affecting $STE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 13, 2026
Corporate Catalyst
Bullish
Impact 65
Jefferies Upgrades STERIS to Buy From Hold, Price Target is $305
Investment firm Jefferies & Co. upgraded STERIS plc from Hold to Buy and established a $305 price target. This analyst upgrade is a positive signal for STERIS, indicating that a pr…
Nov 6, 2026
Corporate Catalyst
Neutral
Impact 65
Analysts Adjust Price Targets for STERIS
UBS and Stephens both increased their price targets for STERIS plc to $290 from $270, with UBS reiterating a Buy rating, and Keybanc maintaining an Overweight rating. These actions…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 92
STERIS Announces Financial Results for Fiscal 2027 Second Quarter
STERIS plc announced robust financial results for its fiscal 2027 second quarter, with total revenue increasing by 9% and constant currency organic revenue growth of 8%. The report…
Oct 12, 2026
Corporate Catalyst
Bullish
Impact 95
STERIS Inks Deal To Acquire Xodus Medical For $2.1B
STERIS plc has announced a major acquisition, agreeing to purchase Xodus Medical for $2.1 billion. This is a significant strategic move for STERIS, expanding its product portfolio …
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Reiterates Overweight on Steris, Raises Price Target to $275
Piper Sandler's reiteration of an 'Overweight' rating and a modest increase in the price target for Steris (STE) signals continued analyst confidence in the company's performance a…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
STERIS Raises Quarterly Dividend From $0.63 To $0.69 Per Share
STERIS plc announced an increase in its quarterly interim dividend from $0.63 to $0.69 per share, payable on September 25, 2026. This marks the company's 21st consecutive year of d…
Jul 28, 2026
Corporate Catalyst
Neutral
Impact 60
UBS Initiates Coverage On Steris with Buy Rating, Announces Price Target of $275
UBS analyst Patrick Wood initiated coverage on Steris (STE) with a 'Buy' rating and set a price target of $275. This event is significant as new analyst coverage, especially with a…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.